Unicycive Therapeutics, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Unicycive Therapeutics filed an 8-K on July 2, 2026 disclosing that the company had an ending cash balance of approximately $61.4 million as of June 30, 2026. No other material events, transactions, counterparties, or business changes are disclosed. The preliminary Q2 2026 results mentioned remain unaudited.
Why this rating
Cash position disclosure is routine for a biotech company. $61.4M is ~95% of company's ~$64.3M market cap, indicating adequate liquidity but no material new event or transaction disclosed.
Extracted items
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.